SAN FRANCISCO, CA--(Marketwire - April 08, 2011) - Medivation, Inc. (NASDAQ: MDVN) today announced that it will hold a teleconference and webcast at 8:30 a.m. Eastern Time, Monday, April 11, to discuss the HORIZON Phase 3 trial results for dimebon (latrepirdine) in patients with Huntington disease. A press release will be issued at 7:30 a.m. Eastern Time Monday prior to this call.
Teleconference/Webcast Details
To participate in the live call on Monday, April 11, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time), please dial 866-582-8907 for domestic callers and +1-678-825-8232 for international callers. In addition, the live conference call is being webcast and can be accessed on the “Events and Presentations” page of the “Investor Relations” section of the Company’s website at www.medivation.com. A replay also will be available for 30 days following the live call. About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Astellas and Pfizer, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer, mild-to-moderate Alzheimer’s disease and Huntington disease. For more information, please visit us at www.medivation.com.
